




Figure 1. PGE₂ enhanced IL-6 secretion in ConA-treated human PBMC.





Figure 2.

The PGE2 concentration-dependence of stimulation of IL-6 secretion by human PBMC without and with ConA-stimulation, and the inhibitory effect of Compound A.

Compound A)



Compound B)




Figure 3. Compound A and Compound B inhibited the IL-6 secretion in ConA-treated PBMC.




Figure 4. Effect of PGE2 application to the human whole blood on the production of IL-6.




Figure 5. Effects of EP2 (butaprost), EP4 (11-deoxy-PGE1) and EP1/EP3 (sulprostone) agonists on the production of IL-6 in HWB.




Figure 6 Effect of Compound B (320-40,000 nM) on the IL-6 production in PGE2-stimulated HWB.




Figure 7. Effect of PGE2 on the production of IL-6 in ConA-stimulated human whole blood (HWB).




Figure 8. Effect of Compound C (16-50,000 nM) on IL-6 production in ConA and PGE2 co-stimulated HWB.